KRAS and non-small cell lung carcinoma: Clinically, mutations and amplifications in NRAS and KRAS have been detected in preclinical EGFR-mutant NSCLC models treated with osimertinib [104,208], and the FLAURA and AURA3 trials identified NRAS and KRAS mutations in up to 3% and 1% of progression cases, respectively [40,50,96,209].